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FoldingUDP-Glucose:glycoprotein glucosyltransferase (UGGT) is a central component of the endoplasmic reticulum (ER)
glycoprotein-folding quality control system, which prevents the exit of partially folded species. UGGT activity can
be regulated by the accumulation of misfolded proteins in the ER, a stimulus that triggers a complex signaling
pathway known as unfolded protein response (UPR) which is closely associated with inﬂammation and disease.
In this work, we investigated the effect of progesterone (P4) on the expression and activity of UGGT in a
mouse hybridoma. We detected the expression of two UGGT isoforms, UGGT1 and UGGT2, and demonstrated
that both isoforms are active in these cells. Interestingly, the expression of each isoform is regulated by high
physiological P4 concentrations. This work provides the ﬁrst evidence of a hormonal regulation of UGGT isoform
expression and activity, whichmight inﬂuence the glycoprotein quality control mechanism. These ﬁndings could
contribute to the study of pathologies triggered by the accumulation of misfolded proteins.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The endoplasmic reticulum (ER) is responsible for the coordination
of protein biosynthetic and secretory activities in the cell; it assists the
maturation of proteins destined for the extracellular environment, the
cellular plasma membrane and the exo/endocytic compartments. The
ﬁdelity of the maturation process is assured by a stringent mechanism
known as the ER quality control system that inhibits the secretion of
folding intermediates, unassembled subunits of oligomeric complexes,
and misfolded polypeptides. This system has been highly studied for
N-glycosylated proteins, where the enzyme UDP-glucose:glycoprotein
glucosyltransferase (UGGT) is a central player [1,2]. UGGT operates as
a gatekeeper as it senses glycoprotein conformation and prevents the
transport of non-native polypeptides out of the ER [3].
N-glycosylation occurs by the addition of preassembled core glycans
(N-acetylglucosamine2-mannose9-glucose3) to nascent polypeptides
emerging in the ER lumen [4]. Sequential trimming of the two outermostterone; UGGT, UDP-Glucose:
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ights reserved.glucose residues, by glucosidase I and gluosidase II respectively, allows
the protein bound N-glycans to associate with the ER lectins calnexin
and calreticulin. This interaction promotes proper protein folding by
preventing protein aggregation and by facilitating the activity of ERp57,
a protein disulﬁde isomerase associated with the lectins that catalyzes
the formation of intra- and intermolecular disulﬁde bonds. Release
from the lectin anchor is followed by glucosidase II cleavage of the
innermost glucose residue. Native polypeptides transit the ER, but
nonnative polypeptides are tagged for reassociation with the lectins
by reglucosylation on N-glycans catalyzed by UGGT. UGGT recognizes
hydrophobic amino acid patches exposed in molten globule-like
conformers [5,6] as well as hydrophobic surfaces exposed in not fully
assembled oligomeric complexes [7]. Lectin binding cycles continues
until glycoproteins either acquire their native structures or are recognized
as irreparably misfolded species and are retro-translocated to the cytosol
for degradation by proteasomes [8,9].
Many physiological stimuli and ﬂuctuations in intracellular
homeostasis disrupt protein folding in the ER, generating the
accumulation of misfolded or unfolded proteins in the organelle. This
condition is known as ER stress and induces a coordinated adaptive
program called the unfolded protein response (UPR) [10]. The UPR
alleviates stress by up-regulating protein folding and degradation
pathways in the ER and inhibiting protein synthesis. In particular,
UGGT expression is regulated during UPR [11,12]. It was demonstrated
that the UPR intracellular signaling pathway responds to metabolic,
3369M.B. Prados et al. / Biochimica et Biophysica Acta 1833 (2013) 3368–3374oxidative stress, and inﬂammatory response pathways [13]. The
cross-talk between the UPR and inﬂammation was observed mostly
in specialized cell types that require the trafﬁcking of large amounts
of proteins through the ER, such as B lymphocytes [14,15]. Moreover,
the UPR has recently been associated with a variety of diseases
including metabolic diseases, inﬂammatory diseases, cancer and
neurodegenerative diseases such as Alzheimer, Parkinson and multiple
sclerosis [16,17]. Therefore, signaling components of the UPR are
emerging as potential targets for novel treatments of human disorders.
On the other hand, while progesterone (P4) has historically been
considered within the context of reproductive functions, it is now clear
that this hormone has effects on the immune system, cardiovascular
system, kidney function, adipose tissue, behavior and respiratory system
[18–21]. Furthermore, P4 has been reported to exert neuroprotective
effects in numerous experimental models. In a model of traumatic brain
injury, P4 regulates the maturation of the NGF neurotrophin [22]. A
completedphase II, randomized, double-blind, placebo-controlled clinical
trial assessing the efﬁcacy of P4 treatment for acute traumatic brain injury
yielded promising results. Fahnestock and colleagues have described that
pro-NGF is increased in Alzheimer´s disease brains [23]. Physiologically
concentrations of P4 have been shown to signiﬁcantly attenuate amyloid
β-peptide-induced toxicity [24]. However, there are only a few reports
regarding P4 regulation of the UPR [25] and, to our knowledge, there
are no reports exploring speciﬁcally the effects of P4 on the components
of the ER glycoprotein quality control system.
Therefore, the aim of this work was to study the effect of P4 on
the expression and activity of UGGT in a mouse hybridoma. We
employed a physiological range of P4 doses in this study: from 10−10M
to 10−5M [21,26–34]. The lowest level of P4 (10−10M) is found in sera
from women during the follicular phase of the menstrual cycle as well
as in men, whereas intermediate concentrations are achieved in sera
from women along the lutheal phase of the menstrual cycle (10−9M to
10−8M) and during pregnancy (10−7M). The highest P4 concentrations
(10−6 to 10−5M) are found locally at the sites of progesterone synthesis
such as gonads, adrenal glands, placenta and brain. Importantly,
relevant effects, inside and outside the reproductive system, were
attributed to the different concentrations tested [18–21,24,26–34].
We detected the expression of two UGGT isoforms in the hybridoma:
UGGT1 and UGGT2.Moreover, our results indicate that both isoforms
are active and can be regulated by high doses of P4. These ﬁndings could
contribute to the study of pathologies triggered by the accumulation of
misfolded proteins.
2. Materials and methods
2.1. Hybridoma cell cultures
The hybridoma 112D5 secreting IgG1 anti-DNP mAb was obtained
by Morelli et al. [35]. Cells (5 × 105 cells/ml) were cultured at 37 °C
and 5% CO2 during 48 h in RPMI 1640 (Gibco-Invitrogen, Carlsbad,
USA) supplemented with 0.2 % NaHCO3, 10% heat-inactivated fetal
bovine serum (Gibco-Invitrogen, Carlsbad, USA), 20 μg/ml penicillin,
20 μg/ml streptomycin, 2 mM L-glutamine and 1 mM pyruvate in the
absence or presence of P4 (10−5, 10−6, 10−8, 10−9 and 10−10 M;
progesterone-water soluble, Sigma-Aldrich, St. Louis, USA) and in the
presence of 5mMdeoxynojirimycin (DJN; glucosidase I and II inhibitor;
Sigma-Aldrich). Cells were recovered by centrifugation at 400g for
10 minutes. Each experiment was repeated 6 times. Cell viability was
determined by Trypan Blue exclusion. Anti-DNP activity was assessed
by ELISA as reported previously [36].
2.2. Cell proliferation assay
Cell proliferation was estimated by measuring DNA synthesis. Cells
were cultured in the conditions described above in a 96-well plate and
were pulsed 18 h before harvesting with 1 μCi/well [3H]-Thymidine20 Ci/mmol (New England Nuclear Corp.; MA, USA). The cells were
subsequently harvested onto glass ﬁber ﬁlters, which were washed,
dried and counted in a Packard 1600 TR scintillation counter. Each
experiment was repeated 3 times.
2.3. Microsomes preparation
Cells were suspended in 5mM Tris–HCl pH 7.4 supplemented with
0.1 M sucrose, β-mercaptoethanol and a protease inhibitor cocktail
(1 μg/ml aprotinin, 1 μg/ml pepstatin and 1 μg/ml leupeptin, all Sigma-
Aldrich, St. Louis, USA). The cell suspension was sonicated at 60 Hz
(2 × 15 s). The cell lysate was then centrifuged at 11,000g for 10 min,
the supernatant was recovered and further centrifuged at 200,000g for
1 hour. The pellet was suspended in 10 mM Tris–HCl pH 8.0. Finally,
protein concentration was determined by Bradford method using BSA
as a standard.
2.4. UGGT enzymatic activity assay
UGGT activity wasmeasured in the hybridomamicrosomal fractions
as the incorporation of [14C]-Glc on denatured tyroglobulin as described
by Trombetta et al. [37]. Brieﬂy, reaction mixtures contained, in a 100μl
ﬁnal volume: Tris–HCl 10mM pH8.0, CaCl2 10mM, Tritón X-100 0.6 %,
UDP-[14C]-Glc 6 μM 285 Ci/M (New England Nuclear Corp.; MA, USA),
deoxynojirimycin 150 μM (Sigma-Aldrich, St. Louis, USA), 300 μg of
microsomal fraction and 500 μg of urea-denatured thyroglobulin.
Reactionmixtureswere incubated for 15minutes at 37°C and the reaction
was stopped with 1 ml of 10% trichloroacetic acid (TCA). Radioactivity
was measured in protein pellets after several washes with TCA with a
Packard 1600 TR scintillation counter. Each determination was done
by triplicate from six independent cell cultures. Enzyme activity was
obtained as cpm/μg of microsomal proteins, the value from non-treated
cells was considered as a unit (arbitrary unit = 1) and the rest of the
values were compared to it.
2.5. Identiﬁcation of mouse UGGT sequences and prediction of the
sub-cellular localization
Mouse UGGT protein sequenceswere identiﬁed by homology search
employing the biosequences analysis software HMMER (HMMER 3.0;
http://hmmer.org/), which is based in the use of hiddenMarkovmodels
(HMMs) of protein's domains. Brieﬂy, the Homo sapiens HUGT1
(NP_064505.1) and HUGT2 (NP_064506.3) protein sequences were
searched iteratively against the UniProtKB/Swiss-Prot (release 2012_08)
and UniProtKB/TrEMBL (release 2012_7) databases employing the
“jackhmmer” program. Then, the criteria for Mus musculus homologues
sequence selection was based on the E value, which threshold was set
at 0.0001, and the presence of two characteristic features of UGGT: the
conserved motif DQDXXN at the C-terminal catalytic domain [3] and
the UDP-g GGTase protein domain (PF06427), as established in the
Pfam database, a collection of protein families represented by multiple
sequence alignments and hidden Markov models [38].
Next, the potential sub-cellular localization of the selected proteins
was predicted by the TargetP software [39]. This software analyses the
N-terminal region of the proteins in the search of signal peptides
and determines the probability of the protein to localize in cellular
compartments or secretion.
2.6. Gene expression analysis
UGGT2 mRNA expression was determined by RT-PCR. Total RNA
from hybridoma cells was extracted with TRI Reagent (Molecular
Research Center Inc; Ohio, USA) following the protocol provided by
the manufacturer. Then, cDNA was synthesized from total RNA using
random primers (Invitrogen, Carlsbad, USA) and MMLV reverse
transcriptase (Promega; Madison, USA). We included a control without
Fig. 1. Progesterone effects on UGGT activity. 112D5 hybridoma cells were incubated for
48 h with increasing doses of progesterone (P4, from 10−10 to 10−5 M). Then, UGGT
enzyme activity was determined in microsomal fractions. The bars represent the mean
value plus the standard deviation of six independent cell cultures. **p b 0.01; ***p b 0.001.
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primers (Integrated DNA Technologies; Iowa, USA): forward ACTTTCC
CACATTGCTTTGGGCTCACTTTCCCACATTGCTTTGGGCTC and reverse AGA
AGGTTATTGGTGGTGCCCTCA. PCR products were separated on a 2.1%
agarose gel and visualized with ethidium bromide.
2.7. Preparation of antibodies
The sequence bearing the 619–643 residues (DLKEMNTEELKGAV
LEKMVGTFVDL) of UGGT2 (NP_001074721.2) that had no similarity
with UGGT1 (NP_942602.2; Supplementary Fig. 1) or any other protein,
as observed in the mouse protein data banks, was selected in order
to synthesize multiantigenic peptides (MAPs; Genbiotech). Polyclonal
antibodies speciﬁc forUGGT2were raised in rabbits using four branched
MAPs. Rabbits were immunized subcutaneously with 1mg/ml of MAPs
plus Freund's adjuvant on days 0, 7, 16 and 25. Afterwards, the animals
were anesthetized and sacriﬁced and the immune sera were employed
for UGGT2 detection.
2.8. Protein expression analysis
UGGT1 and UGGT2 protein expression was analyzed by Western
Blot. Equal amounts of microsomal proteins (1 μg) were loaded
onto SDS-PAGE gels (7.5% polyacrylamide) and then transferred to
nitrocellulose (Hybond-ECL, GE Healthcare, Pittsburgh, USA). The
membranes were blocked with 5% nonfat dried milk in 50mM Tris–HCl,
150 mM NaCl pH 7.5, 1% Tween-20 (T-TBS) at 4 °C overnight. Then,
blots were incubated with a polyclonal rabbit anti-rat UGGT (obtained
and provided by Dr. A. Parodi, Fundación Instituto Leloir, Buenos Aires,
Argentina) or a polyclonal rabbit anti-mouse UGGT2 (obtained by us, as
described in 2.7) at room temperature for 1 hour. After four washes of
5minutes eachwith T-TBS, the blotswere incubated at room temperature
for 1hour with polyclonal goat anti-rabbit IgG conjugated to horseradish
peroxidase (ZyMAX, Invitrogen; Carlsbad, USA). Finally, blots were
developed with enhanced chemiluminescence reagent (Amersham
ECL Advance Western Blotting Detection Kit; GE Healthcare, Pittsburgh,
USA) and exposed to X-ray ﬁlm (AGFA CB) from 15seconds to 6minutes.
Protein expression was determined by densitometry of the blot bands
using the ImageJ 1.42q software (National Institutes of Health, USA).
Densitometry value from non-treated cells was considered as a unit
(arbitrary unit=1) and the rest of the data were related to it.
Since protein expression was analyzed in cell microsomes, loading
controls could not be included. Therefore, as described before [36], six
western blots from independent cell cultures were carried out in each
case, the samples were loaded in different gel positions in each SDS-
PAGE in order to avoidmisinterpretation of the results as a consequence
of any alteration during the protein transference.
2.9. Gene silencing experiments
Two dsRNAs for each target gene (UGGT1 and UGGT2) were custom
synthesized by Invitrogen (Carlsbad, USA). The sequences of the dsRNAs
are the followings: UGGT1 (Ugcgl1: NM_198899.2), oligo 1: UAGGU
CCAGAUACUCUCGCTT and oligo 2: GCGAGAGUAUCUGGACCUATT).
UGGT2 (Ugcgl2: NM_001081252.2): oligo 1: CAGGUGAUGCUCGU
CUGUUUAUAAA and oligo 2: UUUAUAAACAGACGAGCAUCACCUG).
Scrambled sequences of each dsRNAs were also designed (UGGT1:
GCGUGACUAGGUCAAGCUATT and UAGCUUGACCUAGUCACGCTT.
UGGT2: CAGAGGUUCGCCUGUUUAUUUGAAA and UUUCAAAUAAAC
AGGCGAACCUCUG). 1×105 hybridoma 112D5 cells were transfected
with 1 to 150nMdsRNAemploying LipofectamineRNAiMAX (Invitrogen,
Carlsbad, USA) in OptiMEM (Invitrogen, Carlsbad, USA), according to the
protocols depicted by themanufacturer. Cultures were performed during
48 and 72 h in 24-well plates at 37 °C in RPMI (GIBCO-Invitrogen,
Carlsbad, USA) supplemented with 10% fetal bovine serum. The highest
speciﬁc inhibition was achieved with 150 nM dsRNA for UGGT1 oligosand 5 nM for UGGT2 oligos after culturing for 72 h. Besides, P4 10−5M
or 10−6M was added 24 h after the transfection in some cases.
2.10. Statistical analysis
UGGT activity data, obtained as cpm/μg protein, was transformed
with square root function prior to statistical analysis and then normalized
to be easily compared with the protein expression results. One-way
analysis of variance (ANOVA) and "Newman–Keuls Multiple Comparison
Test" were performed to compare mean differences using GraphPad
Prism 5-Graphics Software. P values b0.05 were considered signiﬁcant.
3. Results
Hybridoma cells were cultured with different P4 concentrations
(10−5, 10−6, 10−8, 10−9 and 10−10 M) during 48 h. According to
previously published results [36], cell viability (94 ± 2%) and cell
proliferation (215295 ± 17447 cpm) were not altered with any of
the hormone doses. Moreover, anti-DNP titer was constant along
the studied conditions.
3.1. UGGT activity is regulated by P4 in a dose dependent way
We ﬁrst analyzed whether UGGT activity could be regulated by P4.
To this aim, the enzyme activity was determined in microsomes from
hybridoma cells cultured during 48 h in the presence of increasing P4
concentrations. Results showed that only the highest P4 doses employed
could regulate UGGT activity: 10−6M decreased the activity by 56% and
10−5M increased it by 25% (Fig. 1).
3.2. Hybridoma 112D5 expresses at least two UGGT isoforms whose
expression is modulated by P4
In order to determine whether the modulation of UGGT activity by
P4 was due to a regulation at the protein level, we analyzed UGGT
protein expression bywestern blot employing a rat anti-UGGT antibody
(obtained from Dr. Parodi, Fundación Instituto Leloir, Buenos Aires,
Argentina) that cross reacts with mouse UGGT. In contrast to that
observed in the activity assays, P4 10−5 M signiﬁcantly decreased
UGGT protein expression, while P4 10−6 M had no effect on it
(Fig. 2a). These unexpected ﬁndings prompted us to hypothesize
that the cells expressed at least two UGGT isoforms; while both of
them might have been detected in the activity assay, only one
might have been recognized by the primary antibody in the western
blot. The presence of two UGGT isoforms was previously reported in
humans and were named HUGT1 and HUGT2, but only the former
displayed reglucosylating activity in vitro [11].
Fig. 2. Progesterone effects on UGGT expression. (a) UGGT expression determined by
western blot using a rabbit anti-rat UGGT. Hybridoma cells were incubated for 48 h with
increasingdoses of progesterone (P4, from10−10 to 10−5M). Thebars of thegraph represent
the mean densitometry value plus the standard deviation of six independent cell cultures. A
representative western blot is shown below the graph (b) PCR ampliﬁcation of cDNA
synthesized from total RNA from the 112D5 hybridoma cells: lane 1, molecular weight
standard; lane 2, UGGT2 amplicon of 131 bp; lane 3, negative control (cDNA synthesis
reaction in the absence of reverse transcriptase). Products were resolved in a 2.1% agarose
gel. (c) Western blot of microsomes from the 112D5 hybridoma employing rabbit anti-rat
UGGT (lane 1) and rabbit anti-mouse UGGT2 (lane 2). (d) UGGT2 expression in hybridoma
cells treated for 48 h with P4 as assessed by western blot using a polyclonal anti-mouse
UGGT2. The bars of the graph represent the mean densitometry value plus the standard
deviation of six independent cell cultures. **p b 0.01; ***p b 0.001.
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and HUGT2 in UniProtKB databases, employing the HMMER software.
Then,Mus musculus proteins with E valuesb 0.0001, with the presence
of the Pfam protein domain PF06427 and the presence of the conserved
motif DQDXXN at the C-terminal catalytic domain were selected as
true homologues. This strategy allowed the identiﬁcation of two full
sequences, one homologue to HUGT1 and one homologue to HUGT2.
The sequence annotated as mouse UGGT1 (NP_942602.2) shared 91%
of protein identity and 96% of protein similitude to HUGT1, whereas
the sequence annotated as mouse UGGT2 (NP_001074721.2) shared79% of protein identity and 91% of protein similitude to HUGT2.
Additionally, both sequences bear a signal peptide, as determined
by the TargetP software [39], and an ER retrieval sequence at the
C-terminus: HEEL for UGGT1 and HDEL for UGGT2 (Supplementary
Fig. 1), which is consistent with the protein's cellular function at the ER
and the observations reported for rat and human UGGT homologues
[11,40]. Interestingly, there are only few reports regarding mouse
UGGT1 protein expression and, until now, there are no evidences
reporting mouse UGGT2 protein expression.
Therefore, we ﬁrst designed speciﬁc primers for the detection of
UGGT2. Results showed that hybridoma cells synthesize UGGT2 mRNA
(Fig. 2b, lane 2). This result is supported by the numerous ESTs
(expressed sequence tags) characterized for this transcript in a variety
of mouse tissues (http://www.ncbi.nlm.nih.gov/UniGene; Mm.213406).
Then, we raised a speciﬁc UGGT2 antibody to identify the protein
expression. The antibody was generated by immunizing rabbits with
multi-antigenic peptides bearing the 619–643 residues of UGGT2.
Importantly, this sequence is not present in UGGT1 (Supplementary
Fig. 1). The speciﬁcity of this antiserumwas analyzed bywestern blot
employing microsomes from hybridoma 112D5. We identiﬁed a
band of approximately 173 kDa employing the UGGT2 antibody, in
agreement with the predicted molecular weight of UGGT2. The
western blot analysis employing the rat UGGT antibody detected
mouse UGGT1 speciﬁcally, while the UGGT2 antibody prepared by
us reacted uniquely with UGGT2 (Fig. 2c). UGGT2 band was speciﬁc,
as stripping and re-probing with secondary antibody alone did not
produce any other bands. In agreement with these results, Arnold
et al. observed that the same rat anti-UGGT antibody employed by
us recognized HUGT1 and not HUGT2 [11,41]. Therefore, albeit the
relative abundance of each isoform cannot be determined by western
blot, these results demonstrated that the mouse hybridoma expresses
at least two UGGT isoforms.
Therefore, we next sought to determine whether the discrepancies
observed between UGGT activity and expression in P4-treated cells
were due to the presence and activity of UGGT2. Hence, we repeated
the western blots of P4-treated cells using the UGGT2 polyclonal
antibody. We observed a decrease in UGGT2 expression when cells
were treated with P4 10−6 M and an increase in UGGT2 expression
when P4 concentrationwas 10-5M(Fig. 2d). These results are consistent
with the variations observed in UGGT activity, suggesting that both
isoforms are active in mouse when using the standard activity assay.
3.3. UGGT1 and UGGT2 show in vitro biological activity and are
independently regulated by progesterone
In order to shed light to the contribution of each isoform to the
general UGGT activity and to the regulation exerted by P4, we performed
isoform-speciﬁc knockdowns by RNA interference, employing double
stranded RNA oligos (dsRNA).
Cell viability in the presence of lipofectamine (the transfection
reagent) alone was about 70% and this value was not altered in the
presence of lipofectamine plus the UGGT1 or UGGT2 dsRNA; thus
indicating that the viability reduction observed for silenced cells with
respect to non-treated cells was due solely to lipofectamine toxicity and
not to the enzyme speciﬁc inhibition. Even though UGGT knockout is
lethal in mice, our result is consistent with data observed in other cell
cultures in which viability was indistinguishable from that of the wild
type cells [42]. Silenced cells showed similar anti-DNP titer to wild type
ones in every tested condition; suggesting that UGGT isoforms are
dispensable for IgG1 maturation and further secretion. This result is
supported by similar data obtained by us when cells were cultured in
the presence of 5mMdeoxynojirimycin (DJN), an inhibitor of glucosidase
I and II which prevents the entry of a glycoprotein to the lectin cycle in
the ER.
In the absence of P4, the UGGT1 dsRNA decreased approximately
82% UGGT1 expression (Fig. 3a), without affecting that from UGGT2
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(Fig. 3c). This result shows that UGGT1 is active in the murine
hybridoma and represents the main contributor in the activity assay.
On the other hand, UGGT2 dsRNA reduced a 60% UGGT2 expression
(Fig. 3b), did not alter UGGT1 expression (Fig. 3a) and diminished a
20% the UGGT activity (Fig. 3c). In this case, this result suggests that
UGGT2 is also active in our working conditions, even though to a lesser
extent than UGGT1. All these results are speciﬁc since the incubationFig. 3. UGGT1 and UGGT2 gene silencing experiments. 112D5 hybridoma cells were
transfected employing lipofectamine with double-stranded RNA oligonucleotides (dsRNA)
speciﬁc for UGGT1 (i1) or UGGT2 (i2) for 72 h. In addition, tests were performed by
transfecting cells with scramble dsRNA (includes the nucleotides present in each dsRNA
but in a different sequence (s1 = scramble for UGGT1 and s2 = scramble for UGGT2).
Progesterone (P4 10−5 M or 10−6 M) was added to the culture medium 24 h after
transfection in the indicated cases. Then, (a) UGGT1, (b) UGGT2 expression and (c) UGGT
activity were determined in the cell microsomes. The bars of each graph represent the
mean plus the standard deviation of three independent cell cultures. Pictures of a
representative western blot are shown in each case. *p b 0.05; **p b 0.01; ***p b 0.001;
****p b 0.0001.with scramble dsRNA of each isoform did not produce any variations
in the variables measured (Fig. 3a–c).
When UGGT1 dsRNA treated cells were incubated with P4 10-5 M,
UGGT1 expression was almost abolished (Fig. 3a), UGGT2 expression
was signiﬁcantly increased to a similar level to that observed in wild-
type cells treated with P4 10-5M only (Fig. 3b) and UGGT activity was
similar to non-treated cells (Fig. 3c). These results suggest that the
increased UGGT2 expression observed in the presence of P4 10−5 M
does not respond to a compensatory mechanism triggered by the
reduction in UGGT1 expression or vice versa. Instead, they would
indicate that P4 10−5 M exerts a speciﬁc regulatory mechanism over
each isoform.
At last, the incubation of UGGT2 dsRNA treated cells with P4 10−6M
further reduced UGGT2 expression from 60% to approximately 90%
(Fig. 3b), UGGT1 expression remained unaltered (Fig. 3a) and UGGT
activity was further reduced from 20% to approximately 50% (Fig. 3c).
Having blocked almost all UGGT2, the only source of enzymatic activity
would derive from UGGT1, supporting the observation that UGGT1 is
active in the murine hybridoma.
Altogether, these results indicate that both UGGT1 and UGGT2
proteins expressed by the hybridoma 112D5 contribute to the UGGT
activity assay. In addition, P4 can independently regulate the expression
of each isoform.
4. Discussion
Given the therapeutic beneﬁts reported for progesterone in human
diseases associated with the accumulation of misfolded proteins, in
the present work we investigated whether this hormone could
regulate the expression and activity of UGGT, an UPR-related enzyme.
Interestingly, we detected the existence of two active isoforms of UGGT
in the mouse and provided evidences indicating that P4 regulates the
expression and biological activity of both of them.
This study demonstrates that UGGT activity in hybridoma cells
responds to the highest P4 concentrations of the physiological doses
tested. We found that P4 10−6 M decreased UGGT activity while P4
10−5 M increased it. However, P4 10−6 M did not modify UGGT
protein expression while P4 10−5 M reduced it signiﬁcantly. These
contradictory results led us deﬁne two possible scenarios. On the one
hand, cross-linking experiments revealed that UGGT can associate to a
series of chaperones in the ER [43], suggesting that the enzyme activity
might be regulated through associated proteins. This situation might be
consistent with the observed results when cells were cultured with
P4 10−6 M; however, it was difﬁcult to associate with the effects of
P4 10−5 M. The second possibility arose from the ﬁnding of two
cDNAs encoding human UGGT homologues, named HUGT1 and HUGT2
[11]. Despite the high degree of sequence identity between HUGT1 and
HUGT2, the authors reported that recombinant HUGT2 was not
functional. Considering this ﬁnding and our experimental evidences, we
proposed that the 112D5 murine hybridoma expresses at least two
UGGT isoforms, both of them active as proved by using the standard
UGGT assay, while only one of them was detected by western-blot.
Therefore, we searched for the mouse homologues of HUGTs employing
hidden Markov models by means of the HMMER software. Interestingly,
we found only two proteins, being one of them highly similar to HUGT1
and the other highly similar to HUGT2; these proteins were named
UGGT1 and UGGT2 respectively. Importantly, until now, there was only
clear experimental evidence for the existence of UGGT1 protein [44]. In
this work, we ﬁrst determined UGGT2 mRNA in the hybridoma and
then we detected the protein expression employing a speciﬁc antibody
generated by us. In conclusion, we demonstrated that the 112D5
hybridoma expresses two UGGT isoforms, where UGGT1 was recognized
by the antibody employed previously while UGGT2 was detected by the
antibody obtained in this work.
The biological activity of UGGT1 has been widely demonstrated in
different organisms [41,45], including in the mouse [46]. In this work,
3373M.B. Prados et al. / Biochimica et Biophysica Acta 1833 (2013) 3368–3374we presented evidences that are also in favor of UGGT1 activity, being
the strongest and clearest one that observed in the iRNA experiments
(Fig. 3): in cells treated with UGGT1 dsRNA, UGGT1 expression
diminished approximately 82% whereas the UGGT total activity
decreased 60%. Considering that in this condition UGGT2 expression
was not altered, this result indicates that UGGT1 is active in the
murine hybridoma. Furthermore, it suggests that UGGT1 speciﬁc activity
is the main contributor to the total UGGT activity. Interestingly, several
evidences support the hypothesis that UGGT2 is also biologically active
in the mouse hybridoma cells. Despite not having exceeded a 60%
inhibition in UGGT2 expression in the UGGT2 silencing experiments,
a signiﬁcant decrease in UGGT activity (20%) was observed. This
observation argues in favor of an active UGGT2 isoform. However, in
spite of the fact that both UGGT isoforms were able to transfer UDP-Glc
in vitro, our results indicate that UGGT2 depicted a lower contribution
to the in vitro activity assay than UGGT1. This fact could either indicate
that the assay conditions are optimized for UGGT1 and/or that UGGT2
has a lower speciﬁc enzymatic activity. Moreover, it is interesting to
note that the speciﬁc inhibition of the expression of one isoform did not
induce the expression of the other. Therefore, it is likely that UGGT1
and UGGT2 fulﬁll different roles in the cellular environment, probably
by focusing their activity on a different set of substrates. Recently, Buzzi
et al. [45] demonstrated that uggt2 is an essential gene in Caenorhabditis
elegans and presented several evidences supporting the hypothesis that
the two homologues have distinct biological functions.
The experiments performed in the presence of P4 alone and plus
dsRNA demonstrated that P4 speciﬁcally regulates the expression of
UGGT1 and UGGT2, affecting UGGT total activity. In addition, they
suggest that P4 could alsomodulate UGGT1 andUGGT2 speciﬁc activity.
On the one hand, P4 10−5 M decreased UGGT1 expression (50%),
increased UGGT2 expression (80%) and, in spite of the fact that in the
absence of P4 UGGT1 behaved as the main contributor of the activity
assay, in this case UGGT activity showed amild increase (25%).Moreover,
when UGGT1 knock-down cells were treated with P4 10−5 M, the
increase in UGGT2 expression persists (80%) while an almost complete
decrease in UGGT1 expression was observed without detecting changes
in the enzyme activity. These observations suggest that P4 10−5 M,
besides its effects on UGGT1 and UGGT2 expression, might also up-
regulate UGGT2 speciﬁc activity. On the other hand, cells treated
solely with UGGT2 dsRNA or P4 10−6 M showed an equivalent UGGT1
expression and a similar down-regulation of UGGT2 expression
(50–60%). However, the enzyme activity in the latter condition was
much lower. These results not only indicate that P4 10−6 M down-
regulates the expression of UGGT2 but also suggest that it might
down-regulate UGGT1 speciﬁc activity. This idea is supported by
the results obtained when UGGT2 knock-down cells were cultured
in the presence of P4 10−6 M, where although UGGT1 expression
was similar to the two previous conditions and UGGT2 expression
was almost abolished, the enzyme activity was reduced to the level
observed for wild-type cells in the presence of P4 10−6M (50%).
As stated before, P4 could possibly regulate UGGT isoform activity
through associated proteins. It is important to note that the ER
contains a complex network of molecular complexes that includes
chaperones and foldases [47] and, as previously mentioned, UGGT
can associate to one of them [43]. In addition, UGGT was also found
in a protein complex with the 15-kDa Selenoprotein (Sep15), which
participates in the formation of disulﬁde bonds and its expression is
regulated by dietary selenium and redox homeostasis [44]. Although
it was not speciﬁed in these works, the isoform present in both
complexes was UGGT1, as we could determine after analyzing the
sequences reported in both of them. These observations support
the hypothesis that the speciﬁc activity of UGGT1 could be regulated
through the modulation of associated proteins. Although until now,
there is no evidence of the presence of UGGT2 in protein complexes,
we cannot discard that it might require an associated protein for
catalytic activity.The fact that P4 10−6M and 10−5M produced opposite effects on
UGGT activity in hybridoma cells is intriguing. P4 is a steroid
hormone that typically binds to its intracellular receptors (nPR),
which mediate many of the physiological effects of P4 by regulating
gene expression. The expression of nPR in the hybridoma was
already described [48] and conﬁrmed by us (data not shown).
However, P4 also exerts non-transcriptional effects that have been
shown to rely on membrane P4 receptors (mPR). What is more,
evidence suggesting a cross-talk between nPR and mPR have
recently emerged [49]. Until now, the mPR family includes mPR α,
β and γ and the recently described mPR δ and ε [49–52]. In addition,
the progesterone receptor membrane component 1 (PGRMC1) is
another prospective candidate mediating the non-genomic actions
of progesterone. Until now, we detected the expression of mPRγ
in the hybridoma's plasma membrane. Interestingly, employing a
P4-BSA-FITC conjugate (which is unable to diffuse through the cell
membrane) we observed, by ﬂow cytometry, hormone binding
to the hybridoma plasma membrane at P4 10−5 M and not at P4
10−6 M. Moreover, our studies suggest that both nuclear and
membrane receptors are differentially involved in the regulation
of UGGT1 and UGGT2 expression and activity (unpublished data).
We are currently studying the complex intracellular mechanism
regulated by P4 concentrations that might be operating in the
hybridoma.
The difference in activity between UGGT2 and HUGT2 could be
related to some variations along the primary sequence that could
affect their conformation and/or enzymatic activity. The catalytic
site boundaries have been deﬁned by Arnold et al. [11]. Interestingly,
UGGT2, unlike HUGT2, retains the lysine 1294 in the catalytic site, an
amino acid present in all UGGThomologues except HUGT2. Nevertheless,
the differences in activity might also arise from the recombinant nature
of HUGT2.
On the other hand, IgG1 titer was not altered neither in UGGT
silenced cells (UGGT1 or UGGT2) nor in those cells cultured in the
presence of DJN. These results indicate that the inability to enter
into the lectin cycle and consequently in the ER glycoprotein
quality control mechanism (including UGGT1 and UGGT2) did
not affect, in particular, hybridoma IgG1 maturation and secretion.
This observation is consistent with several evidences showing that
IgG1 proper assembly and secretion is regulated by the molecular
chaperone BiP; the mechanism implicated was described in detail
by Feige et al. [53].
Finally, it was previously reported that UGGT activity can be
modulated by the accumulation of misfolded proteins in the ER
triggered by several stressors such as tunicamycin, an N-glycosylation
blocking compound or the ionophore A-23187 [11,12]. In this work
we show the ﬁrst evidence of the regulation of UGGT activity by a
physiological stimulus. Interestingly, we also observed a correlation
between P4 concentration in serum from healthy women along
the two phases of the menstrual cycle and UGGT activity from B
lymphocytes isolated from the same blood samples (unpublished
data).5. Conclusions
This work reports the expression and activity of two UGGT mouse
isoforms. Moreover, it provides the ﬁrst evidence of a hormonal
regulation of both UGGT1 and UGGT2 protein expression and activity,
bringing a new approach to study the regulation of the quality control
mechanism of glycoproteins by P4 in health and disease. These results
might be especially important in the study of pathologies triggered by
the accumulation of misfolded proteins as well as for the study of sex
differences in the manifestations of some diseases.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2013.09.022.
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